Allergan Investor Suit Over Botox Deal Put On Hold

Law360, New York (January 21, 2011, 9:00 PM ET) -- A judge stayed proceedings Friday in an Allergan Inc. shareholder derivative suit seeking to force the company’s board to cover a $600 million settlement with the U.S. over off-label Botox uses, allowing another shareholder to investigate the claims and potentially intervene.

Vice Chancellor J. Travis Laster of the Delaware Court of Chancery stayed an upcoming motion to dismiss the suit — which stems from Allergan’s settlement of allegations relating to off-label uses of its Botox drug — to allow a second potential plaintiff to conduct discovery...
To view the full article, register now.